Skip to main content
OpenTrials

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

9,951 public trials 2,018 recruiting studies
Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Recruiting

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

NCT03681561

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • University of Illinois Cancer Center Chicago, Illinois, United States
  • Indiana Melvin and Bren Simon Comprehensive Cancer Center Indianapolis, Indiana, United States
  • University of Iowa Hospitals and Clinics Iowa City, Iowa, United States
  • University of Minnesota Minneapolis, Minnesota, United States
View Trial Details
Recruiting

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

NCT06980116

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Chronic Disease, +38 more
Locations
  • LLC ARENSIA Exploratory Medicine Tbilisi, Georgia
  • IMSP Institute of Oncology, ARENSIA Exploratory Medicine Chisinau, Moldova
  • Hospital Beata Maria Ana Madrid, Spain
  • Hospital Fundación Jiménez Diaz Madrid, Spain
View Trial Details
Recruiting

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

NCT06730126

Conditions
Autoimmune Diseases, Autoimmune Lymphoproliferative Syndrome, Autoimmune Lymphoproliferative Syndrome, Type IA, +9 more
Locations
  • National Institutes of Health Clinical Center Bethesda, Maryland, United States
  • The Children's Hospital of Philadelphia Philadelphia, Pennsylvania, United States
  • Texas Children's Hospital Houston, Texas, United States
View Trial Details
Recruiting

PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.

NCT05947136

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Complication, +13 more
Locations
  • CH Annecy Genevois Épagny, France
  • CHU La Tronche Grenoble, France
  • Centre Léon Bérard Lyon, France
  • CENTRE HOSPITALIER UNIVERSITAIRE de MONTPELLIER Montpellier, France
View Trial Details
Recruiting

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

NCT07095452

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Hospital Scottsdale /ID# 278349 Scottsdale, Arizona, United States
  • Cedars-Sinai Medical Center /ID# 278238 Los Angeles, California, United States
  • Colorado Blood Cancer Institute /ID# 279080 Denver, Colorado, United States
  • Winship Cancer Institute of Emory University /ID# 277667 Atlanta, Georgia, United States
View all 49 locations
View Trial Details
Recruiting

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

NCT07439653

Conditions
Hemic and Lymphatic Diseases, Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, Immune System Diseases, +8 more
Locations
  • UCLA Santa Monica, California, United States
  • Stanford University Stanford, California, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View Trial Details

Related conditions